The chief scientific officer of US pharmaceutical company Johnson & Johnson Inc (J&J), Paul Stoffels, said on 1 March 2021 that the company is waiting on regulatory approval of a new, larger plant operated by contract manufacturer Catalent Inc to begin large-scale US deliveries of its just-authorised COVID-19 vaccine following initial shipments this week, Reuters news agency reported on Tuesday.
Reportedly, J&J will ship nearly four million doses of its one-shot COVID-19 vaccine around the US this week and expects to deliver another 16 million doses later this month. However, no doses are expected to go out next week.
Stoffels was quoted as saying in an interview: "The first doses come from a smaller plant, which we could start up earlier. The big plant is on board, the FDA is looking at all the quality data and hopefully very quickly, we'll be able to get approval to ship from that plant and then we get going."
Stoffels added he expects the Catalent plant to receive approval in the next few days and the company would be able to meet its promise to supply 20 million doses of the vaccine by the end of March 2021.
President for Catalent North America, Mike Riley, stated: "Catalent is on track to deliver on our commitments for Johnson & Johnson COVID-19 vaccine deliveries as soon as we are approved to begin shipments by the FDA, which we anticipate in the coming weeks."
J&J is also working to expand its manufacturing capacity globally and is in talks with potential new partners, Stoffels said, adding that he expects to be able to announce more manufacturing deals soon.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML